Journal
CELL CHEMICAL BIOLOGY
Volume 26, Issue 9, Pages 1214-+Publisher
CELL PRESS
DOI: 10.1016/j.chembiol.2019.06.005
Keywords
-
Categories
Funding
- Max Planck Society
- European Research Council under the European Union's Seventh Framework Program (FP7/2007-2013, ERC) [268309]
- International Max Planck Research School
- Alexander von Humboldt-Stiftung
Ask authors/readers for more resources
Cancer cells sustain growth by altering their metabolism to accelerated aerobic glycolysis accompanied by increased glucose demand and employ glutamine as additional nutrient source. This metabolic adaptation induces upregulation of glucose transporters GLUT-1 and -3, and simultaneous targeting of both transporters and of glutamine metabolism may offer a promising approach to inhibit cancer cell growth. We describe the discovery of the very potent glucose uptake inhibitor Glutor, which targets glucose transporters GLUT-1, -2, and -3, attenuates glycolytic flux and potently and selectively suppresses growth of a variety of cancer cell lines. Co-treatment of colon cancer cells with Glutor and glutaminase inhibitor CB-839 very potently and synergistically inhibits cancer cell growth. Such a dual inhibition promises to be particularly effective because it targets the metabolic plasticity as well as metabolic rescue mechanisms in cancer cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available